Target intelligence / Profile preview

Serine-rich and transmembrane domain-containing 2 (SERTM2)

Target
SERTM2
Molecular classification
Micropeptide (type I transmembrane), Long non-coding RNA (lncRNA), Other (as a bifunctional genomic locus; produces peptide OR lncRNA depending on context)
01

Overview

SERTM2 refers to a gene locus encoding both a serine-rich, single-pass transmembrane micropeptide and a long non-coding RNA. The micropeptide is 89 amino acids long, enriched in motor neuron plasma membranes, and modulates neuronal excitability and resting membrane potential by interacting with the TASK1 potassium channel. In the heart, the SERTM2 locus (often referred to by aliases such as CARDEL or LINC00890) generates an lncRNA activated during human cardiac development; this RNA is required for proper cardiac cell specification and differentiation, and its knockout impairs heart formation. The gene is bifunctional: in some tissues (notably motor neurons), it is translated as a micropeptide, while in others (notably heart), its function appears to be mediated by the lncRNA alone.

Other names
SERTM2CARDEL (Cardiac Development Long non-coding RNA)LINC00890DKFZp686D0853long intergenic non-protein coding RNA 890lncMN3serine-rich and transmembrane domain-containing 2
02

Mechanism of action

Not applicable; no drug mechanisms targeting SERTM2 known at present

03

Biological functions

Modulates motor neuron excitability through interaction with potassium channels (TASK1)Contributes to resting membrane potential in neuronsRegulates cardiac specification and homeostasis during development (lncRNA function)
04

Disease associations

Potential role in neurological function (motor neuron physiology)Proven role in cardiac development; knockout disrupts cardiomyocyte fate specificationImplicated in cardiac diseases via abnormal expression patterns (lncRNA forms)
05

Biomarkers

Potential for lncRNA forms (CARDEL, LINC00890) to serve as developmental or disease biomarkers in cardiac tissue (not clinically validated)

Beyond the preview

Go deeper on Serine-rich and transmembrane domain-containing 2 (SERTM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serine-rich and transmembrane domain-containing 2 (SERTM2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call